Abstract
The long-term effects of niceritrol on lipoprotein(a) (Lp[a]), lipids, apolipoproteins, and fibrinogen and fibrinolytic factors were evaluated in 20 out-patients who had serum Lp(a) levels higher than 20 mg/dL. The mean (±SE) levels of Lp(a) decreased from 33.6 ± 2.3 mg/dL to 23.5 ± 3.5 mg/dL after 12 months of niceritrol treatment (P < 0.01). Serum levels of triglycerides and apoliprotein E decreased significantly and high-density lipoprotein cholesterol (HDL-C) increased significantly after 12 months (P < 0.05). There were no significant changes overall in fibrinogen and fibrinolytic factors, although fibrinogen concentrations showed a tendency to decrease with treatment. PAI-1 levels decreased significantly (P < 0.05) after 6 months of niceritrol treatment. A significant correlation of percent reduction between Lp(a) and apolipoprotein B levels (P < 0.01) was observed, suggesting that the Lp(a)-lowering effects of niceritrol may be due to niceritrol inhibition of apolipoprotein B synthesis, the major apolipoprotein of Lp(a). The ability of niceritrol to decrease Lp(a) levels and increase HDL-C levels, together with its tendency to lower fibrinogen levels, may help prevent coronary events in patients with high levels of Lp(a).
| Original language | English |
|---|---|
| Pages (from-to) | 52-59 |
| Number of pages | 8 |
| Journal | Clinical therapeutics |
| Volume | 17 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 01-01-1995 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pharmacology
- Pharmacology (medical)
Cite this
}
Long-term effects of niceritrol on serum lipoprotein(a) and lipids in patients with high levels of lipoprotein(a). / Yamauchi, Kazunobu; Tanahashi, Yoshifumi; Okada, Mitsuhiro; Tsuzuki, Jitsuki; Sato, Akihiko; Abe, Kazunari; Inagaki, Haruo; Agetsuma, Hirotaka; Hattori, Ritsuo; Izawa, Hideo.
In: Clinical therapeutics, Vol. 17, No. 1, 01.01.1995, p. 52-59.Research output: Contribution to journal › Article
TY - JOUR
T1 - Long-term effects of niceritrol on serum lipoprotein(a) and lipids in patients with high levels of lipoprotein(a)
AU - Yamauchi, Kazunobu
AU - Tanahashi, Yoshifumi
AU - Okada, Mitsuhiro
AU - Tsuzuki, Jitsuki
AU - Sato, Akihiko
AU - Abe, Kazunari
AU - Inagaki, Haruo
AU - Agetsuma, Hirotaka
AU - Hattori, Ritsuo
AU - Izawa, Hideo
PY - 1995/1/1
Y1 - 1995/1/1
N2 - The long-term effects of niceritrol on lipoprotein(a) (Lp[a]), lipids, apolipoproteins, and fibrinogen and fibrinolytic factors were evaluated in 20 out-patients who had serum Lp(a) levels higher than 20 mg/dL. The mean (±SE) levels of Lp(a) decreased from 33.6 ± 2.3 mg/dL to 23.5 ± 3.5 mg/dL after 12 months of niceritrol treatment (P < 0.01). Serum levels of triglycerides and apoliprotein E decreased significantly and high-density lipoprotein cholesterol (HDL-C) increased significantly after 12 months (P < 0.05). There were no significant changes overall in fibrinogen and fibrinolytic factors, although fibrinogen concentrations showed a tendency to decrease with treatment. PAI-1 levels decreased significantly (P < 0.05) after 6 months of niceritrol treatment. A significant correlation of percent reduction between Lp(a) and apolipoprotein B levels (P < 0.01) was observed, suggesting that the Lp(a)-lowering effects of niceritrol may be due to niceritrol inhibition of apolipoprotein B synthesis, the major apolipoprotein of Lp(a). The ability of niceritrol to decrease Lp(a) levels and increase HDL-C levels, together with its tendency to lower fibrinogen levels, may help prevent coronary events in patients with high levels of Lp(a).
AB - The long-term effects of niceritrol on lipoprotein(a) (Lp[a]), lipids, apolipoproteins, and fibrinogen and fibrinolytic factors were evaluated in 20 out-patients who had serum Lp(a) levels higher than 20 mg/dL. The mean (±SE) levels of Lp(a) decreased from 33.6 ± 2.3 mg/dL to 23.5 ± 3.5 mg/dL after 12 months of niceritrol treatment (P < 0.01). Serum levels of triglycerides and apoliprotein E decreased significantly and high-density lipoprotein cholesterol (HDL-C) increased significantly after 12 months (P < 0.05). There were no significant changes overall in fibrinogen and fibrinolytic factors, although fibrinogen concentrations showed a tendency to decrease with treatment. PAI-1 levels decreased significantly (P < 0.05) after 6 months of niceritrol treatment. A significant correlation of percent reduction between Lp(a) and apolipoprotein B levels (P < 0.01) was observed, suggesting that the Lp(a)-lowering effects of niceritrol may be due to niceritrol inhibition of apolipoprotein B synthesis, the major apolipoprotein of Lp(a). The ability of niceritrol to decrease Lp(a) levels and increase HDL-C levels, together with its tendency to lower fibrinogen levels, may help prevent coronary events in patients with high levels of Lp(a).
UR - http://www.scopus.com/inward/record.url?scp=0028940024&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028940024&partnerID=8YFLogxK
U2 - 10.1016/0149-2918(95)80006-9
DO - 10.1016/0149-2918(95)80006-9
M3 - Article
VL - 17
SP - 52
EP - 59
JO - Clinical Therapeutics
JF - Clinical Therapeutics
SN - 0149-2918
IS - 1
ER -